# Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

> **NCT01299727** · PHASE1,PHASE2 · TERMINATED · sponsor: **Shire** · enrollment: 12 (actual)

## Conditions studied

- Sanfilippo Syndrome

## Interventions

- **BIOLOGICAL:** rhHNS-10 mg
- **BIOLOGICAL:** rhHNS-45 mg
- **BIOLOGICAL:** rhHNS-90 mg

## Key facts

- **NCT ID:** NCT01299727
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03-01
- **Primary completion:** 2019-04-12
- **Final completion:** 2019-04-12
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Completion of follow-up period
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01299727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01299727, "Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01299727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*